# Roche CEO Thomas Schinecker cites 'mind-blowing' bureaucracy as a major hurdle.

*biotech · news · 2026-04-23 · Devdiscourse*

## Key points

- Roche CEO Thomas Schinecker warns Europe's pharma sector risks falling behind the U.S. and China.
- Schinecker identifies excessive bureaucracy in Europe as a significant barrier for pharmaceutical innovation.
- U.S. policy tying drug prices to cheaper foreign alternatives impacts European drug launch strategies.
- Roche and Sanofi remain committed to European markets, actively negotiating pricing amid regulatory challenges.

Europe's pharmaceutical industry is under strain as it risks trailing the U.S. and China, warned Roche CEO Thomas Schinecker, citing 'mind-blowing' bureaucracy as a major hurdle. This warning follows U.S. President Trump's policy linking American drug prices to cheaper alternatives abroad, significantly affecting European launches. Despite acknowledging the challenges, industry leaders from Roche and Sanofi emphasize their commitment to introducing new drugs in Europe, negotiating pricing strategies to sustain innovation and market access. (With inputs from agencies.)

**Companies:** Roche, Sanofi
**Countries:** Switzerland, France, United States

[Read the full story on Devdiscourse](https://www.devdiscourse.com/article/business/3884466-europes-pharma-industry-faces-challenges-amid-global-competition)

---

Canonical: https://newsio.io/n/a9faa221-f896-48b8-964b-1506db7c23dc/roche-ceo-thomas-schinecker-cites-mind-blowing-bureaucracy-as-a-major-hurdle-thi
Summarized by Newsio from Devdiscourse. https://newsio.io/how-it-works